Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:7177 |
Name | anal canal squamous cell carcinoma |
Definition | An anal canal cancer that derives_from epithelial squamous cells. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer intestinal cancer large intestine cancer anal canal cancer anal canal squamous cell carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
Unknown unknown | Cetuximab + Cisplatin + Fluorouracil + Radiotherapy | anal canal squamous cell carcinoma | not applicable | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02314169 | Phase II | Nivolumab | Nivolumab in Treating Patients With Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal | Recruiting | USA | CAN | 0 |
NCT02879162 | Phase II | Durvalumab + Tremelimumab | Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours | Active, not recruiting | CAN | 0 |
NCT03074513 | Phase II | Atezolizumab + Bevacizumab | Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors | Active, not recruiting | USA | 0 |
NCT03517488 | Phase I | XmAb20717 | A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) | Recruiting | USA | 0 |
NCT03597295 | Phase II | Retifanlimab | A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy | Active, not recruiting | USA | 5 |
NCT03894618 | Phase I | SL-279252 | SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas | Recruiting | USA | CAN | 2 |
NCT04429542 | Phase I | BCA101 BCA101 + Pembrolizumab | Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors | Recruiting | USA | CAN | 0 |
NCT04521413 | Phase Ib/II | CFI-402411 + Pembrolizumab CFI-402411 | Safety and Efficacy Study Of CFI-402411 in Subjects With Advanced Solid Malignancies | Recruiting | USA | CAN | 1 |